A5081187428- Cytomegalovirus and herpesvirus research
- Herpesvirus Infections and Treatments
- Transplantation: Methods and Outcomes
- Pneumocystis jirovecii pneumonia detection and treatment
- Polyomavirus and related diseases
- Renal Transplantation Outcomes and Treatments
- Neurological Complications and Syndromes
- Anesthesia and Pain Management
- Organ and Tissue Transplantation Research
- Trauma Management and Diagnosis
- Toxoplasma gondii Research Studies
- Hematological disorders and diagnostics
- HIV/AIDS drug development and treatment
- Airway Management and Intubation Techniques
- HIV Research and Treatment
- Complement system in diseases
- Bone and Joint Diseases
- Infectious Diseases and Tuberculosis
- Hepatitis C virus research
- Antifungal resistance and susceptibility
- Peripheral Neuropathies and Disorders
- Nausea and vomiting management
- Infectious Encephalopathies and Encephalitis
- Pharmacological Effects and Toxicity Studies
UW Health University Hospital
2021-2025
University of Wisconsin Health
2025
Northwestern Memorial Hospital
2023-2024
Background: Letermovir is approved for primary prophylaxis of cytomegalovirus (CMV) in high-risk kidney transplant recipients. However, many experts suggest the drug be reserved as a second-line agent when valganciclovir not tolerated or fails. Objective: The purpose this study was to describe feasibility de novo letermovir prophylactic approach CMV and seropositive abdominal solid organ patients. Methods: Retrospective review recipients who required between June 6, 2023, 2024. evaluate...
Cytomegalovirus (CMV) is a driver of negative outcomes after lung transplant (LTX) and primary prophylaxis (PPX) with valganciclovir (VGC) standard-of-care. VGC associated myelosuppression, prompting interest in letermovir (LTV).
To evaluate the association of conversion from valganciclovir to letermovir on cytomegalovirus-specific cellular immunity.Adult patients were included if they received a kidney or liver transplant between 8/1/2018-12/31/20, developed symptomatic, high-level CMV viremia and converted 480 mg daily as monotherapy after treatment with ganciclovir-derivatives for minimum 4 weeks had subsequent cell-mediated immunity (CMI) testing via ICS assay by flow cytometry (Viracor Eurofins T Cell Immunity...
ABSTRACT Background Cytomegalovirus (CMV) drives negative outcomes after liver transplant (LT), with patients having high‐risk serostatuses (D+/R−) being especially vulnerable. While valganciclovir (VGC) remains the standard‐of‐care, letermovir (LTV) represents a promising potential in LT, given reduced myelosuppression. Methods Adult receiving an LT CMV serostatus June 1, 2021–June 6, 2024 were evaluated. Patients included standard‐of‐care (SOC) or LTV cohort based on de novo antiviral...
IntroductionInadequate pain control after lung transplantation increases perioperative complications. Standard opioid-based regimens are associated with adverse effects and epidural catheters that reduce opioid use limited by contraindications technical challenges. We report the of intercostal nerve cryoablation to enhance as part an opioid-sparing protocol for transplant recipients (LTR).MethodsWe conducted a retrospective cohort study LTRs from 1/1/2016-12/31/2021, before (pre-cryo)...
Cytomegalovirus (CMV) is associated with detrimental outcomes after lung transplantation (LTX); primary prophylaxis (PPX) valganciclovir (VGC) guideline-recommended. VGC myelosuppression, spurring interest in letermovir (LTV).
To evaluate epidemiology, risk-factors, and outcomes of high-level (HL) cytomegalovirus (CMV) viremia in liver transplant recipients.Adult patients receiving a between 1/1/2017 9/30/2020 were evaluated. Viral loads at University Wisconsin Health Clinical Laboratories required to allow for numerical comparison. Primary objective was incidence HL CMV (viral-load > 100 000 IU/ml). Secondary elucidate risk factors targeted interventions.Two hundred nine met inclusion criteria; 175 kept their...
image
Studies conducted in the northern United States found cytomegalovirus (CMV) disease after liver transplantation follows a seasonal pattern, with increased incidence fall and winter. This has not been evaluated kidney transplant recipients. Improved understanding of CMV seasonality may help guide use preventative therapies.We adult patients receiving at our center Wisconsin from January 1, 1995 to December 31, 2018. event was defined as quantifiable viral replication clinical signs or...
Abstract Background While presumably less common with modern molecular diagnostic and imaging techniques, fever of unknown origin (FUO) remains a challenge in kidney transplant recipients (KTRs). Additionally, the impact FUO on patient graft survival is poorly described. Methods A cohort adult KTRs between January 1, 1995 December 31, 2018 was followed at University Wisconsin Hospital. Patients transplanted from to 2005 were included “early era”; patients 2006 “modern era”. The primary...